BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31622868)

  • 1. Synthesis, molecular modeling and anti-cancer evaluation of a series of quinazoline derivatives.
    Khodair AI; Alsafi MA; Nafie MS
    Carbohydr Res; 2019 Dec; 486():107832. PubMed ID: 31622868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indolylmethylene benzo[h]thiazolo[2,3-b]quinazolinones: synthesis, characterization and evaluation of anticancer and antimicrobial activities.
    Gali R; Banothu J; Porika M; Velpula R; Hnamte S; Bavantula R; Abbagani S; Busi S
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4239-42. PubMed ID: 25096298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and molecular modeling studies of 2-styrylquinazoline derivatives as EGFR inhibitors and apoptosis inducers.
    Amin NH; Elsaadi MT; Zaki SS; Abdel-Rahman HM
    Bioorg Chem; 2020 Dec; 105():104358. PubMed ID: 33074119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
    Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
    El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
    Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
    Zhou Z; He J; Yang F; Pan Q; Yang Z; Zheng P; Xu S; Zhu W
    Bioorg Chem; 2021 Jul; 112():104848. PubMed ID: 33819737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS; Elshihawy HE; Said MM; Abouzid KA
    Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers.
    El-Sharief AMS; Ammar YA; Belal A; El-Sharief MAMS; Mohamed YA; Mehany ABM; Elhag Ali GAM; Ragab A
    Bioorg Chem; 2019 Apr; 85():399-412. PubMed ID: 30665034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, Cytotoxicity and Molecular Docking Studies of the 9-Substituted 5-Styryltetrazolo[1,5-c]quinazoline Derivatives.
    Mphahlele MJ; Gildenhuys S; Parbhoo N
    Molecules; 2017 Oct; 22(11):. PubMed ID: 29072619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
    OuYang Y; Zou W; Peng L; Yang Z; Tang Q; Chen M; Jia S; Zhang H; Lan Z; Zheng P; Zhu W
    Eur J Med Chem; 2018 Jun; 154():29-43. PubMed ID: 29775935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
    Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
    Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
    Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
    Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
    El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative and Antiangiogenic Properties of New VEGFR-2-targeting 2-thioxobenzo[
    Abuelizz HA; Marzouk M; Bakheit AH; Awad HM; Soltan MM; Naglah AM; Al-Salahi R
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33333992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
    Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
    Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.